A part of Watch Media

MedWatchThursday8 June 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday8 June 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Photo: Anna Gordon/Reuters/Ritzau Scanpix

EU Commission approves first RSV vaccine for people over 60

A recommendation from the EMA’s expert panel from earlier this year has now been cemented.
  • Pfizer’s RSV shot wins US approval following GSK’s to market
  • First RSV vaccine caps 60-year search to stem pervasive lung illness

For subscribers

Christian Grøndahl, co-founder and CEO of Snipr Biome | Photo: Snipr Biome/pr

Snipr Biome shelves lead candidate: "It’s hard to make money within AMR"

For subscribers

Photo: George Frey/Reuters/Ritzau Scanpix

UK looks to expand obesity-drug access with pilot program

For subscribers

Photo: George Frey/Reuters/Ritzau Scanpix

Denmark warns against overtreatment with Ozempic

For subscribers

Photo: Darron Cummings/AP/Ritzau Scanpix

Takeda, Eli Lilly must defend racketeering suit over diabetes drug, judge rules

For subscribers

Photo: Brendan Mcdermid/Reuters/Ritzau Scanpix

Merck sues US, calling move to cut drug prices "extortion"

For subscribers

  • The launch of Wegovy could change the pharmaceuticals market, says a Stifel's investment advisor | Foto: Novo Nordisk / Pr

    Analyst predicts golden future for GLP-1 as drugmakers rush to join in

    Novo Nordisk’s launch of weight-loss drug Wegovy has pushed the market for the medical treatment of chronic diseases like diabetes and obesity.

    For subscribers

  • Photo: Zealand Pharma / PR

    Zealand Pharma reprimanded by Danish watchdog following sale of rescue pen to Novo Nordisk

    The biotech company classified information as internal knowledge too late when negotiating a deal with Novo Nordisk, says the Danish Financial Supervisory Authority.

    For subscribers

  • There's excitement in the air at Hørsholm-based Technolution, as the company will be bought by US-based MGS | Photo: Technolution / Pr

    US contract manufacturer acquires Danish consultancy firm

    Medical device maker MGS is taking over another company in Denmark.

    For subscribers

  • Scientists from Rigshospitalet attended some of the first trials of both epcoritamab and glofitamab, both of which are bispecific antibodies against hematologic cancers. | Photo: Jens Dresling/Ritzau Scanpix

    Genmab approval marks the era of bispecific antibodies in blood cancer treatment, says expert

    In coming years, doctors will receive more ways to treat patients with hematologic cancers.

    For subscribers

  • Foto: Issei Kato/Reuters/Ritzau Scanpix

    Eisai hit by ransomware attack

    Pharmaceutical firm Eisai informs that it will take some time to understand the full scope of the incident and that recovery efforts have been initiated.

    For subscribers

  • Foto: Dado Ruvic/Reuters/Ritzau Scanpix

    GPT AI has arrived in the doctor's office

    Artificial is now taking notes for doctors, allowing them to focus on patients. ”This type of technology will make doctors more likely to stay in their jobs,” says Carbon Health’s innovation officer. 

    For subscribers

  • Other countries have also reported of supply issues concerning diabetes drug Ozempic | Photo: Lægemiddelstyrelsen/pr

    Denmark warns of Novo Nordisk diabetes drug shortage

    As soon as mid-July, the Danish Medicines Agency expects supply improvements from the drugmaker.

    For subscribers

  • Jakob Knudsen, CEO of ViroGates | Photo: Virogates / Pr

    Sobi partners with ViroGates on Covid-19 combination treatment for US market

    Danish diagnostics firm ViroGates and Swedish Sobi look forward to commencing dialogs with the US drug authority.

    For subscribers

  • Photo: George Frey/Reuters/Ritzau Scanpix

    Nanexa preparing for phase I trial of Novo Nordisk drug in slow-release injection

    A depot injection of liraglutide would simplify treatment for patients with obesity and diabetes, says Nanexa, which is gearing up to start testing later this year.

    For subscribers

  • Pharmaceutical company Pfizer has gotten one step closer to a market approval of its drug candidate ATM-AVI. | Foto: Carlo Allegri/Reuters/Ritzau Scanpix

    Pfizer presents promising phase III data for new antibiotic treatment

    A new combination treatment from Pfizer shows strong effects in a late-stage trial treating serious infections caused by drug-resistant bacteria.

    For subscribers

  • Photo: Novo Nordisk / Pr

    Novo Nordisk to buy French developer of digital injection pen add-on

    After around two years of being partnered, the Danish drugmaker wants to take over Biocorp.

    For subscribers

  • Photo: Pool New

    Novo Nordisk maintains its defense in case of high-priced insulin – competitor enters settlement

    Novo Nordisk rejects the US charges of price fixing for insulin while competitor Eli Lilly settles in the case.
  • Photo: Klatka Grzegorz/AP/Ritzau Scanpix

    Multi-cancer blood test spots two in three cases in UK study

    A blood test for over 50 types of cancer correctly identified the disease in two-thirds of cases in a major trial in England and Wales.

    For subscribers

  • The UK's health regulator NICE have given its stamp of approval to migraine treatment drug Vydura (rimegepant). It is known as Nurtec in the US and is marketed outside the country by Pfizer. | Photo: v

    NICE approves migraine wafer from Pfizer

    The British regulatory body, NICE, has approved the wafer Vydura from Biohaven/Pfizer as a preventive measure against migraines but not as acute treatment.

    For subscribers

  • Photo: Alk / Pr

    ALK pushed out of leading European index

    The allergy company will be replaced by a Danish cable manufacturer. 
  • Foto: Mike Blake/Reuters/Ritzau Scanpix

    Eli Lilly enters multimillion-dollar settlement on US insulin prices

    Novo Nordisk and Sanofi aren’t entailed by the settlement in the class-action lawsuit that claims the three companies simultaneously overpriced their insulin products.

    For subscribers

  • Photo: Genmab PR og /ritzau Scanpix/Stine Tidsvilde

    Novo Nordisk launches another phase III study of Genmab-developed hemophilia drug

    A new phase III study will test the safety of switching from Roche’s blockbuster medicine to Novo Nordisk’s similar solution for people with a bleeding disorder.

    For subscribers

  • Michael Engsig, CEO of Nykode Therapeutics | Photo: Anne Grete Storvik

    Nykode expands collaboration with Roche on cervical cancer vaccine

    A new study of Nykode’s vaccine candidate in combination with Roche’s Tecentriq will hopefully give patients access to new treatment.

    For subscribers

  • Photo: Johanna Geron/Reuters/Ritzau Scanpix

    Pfizer’s RSV shot wins US approval following GSK’s to market

    The second vaccine against respiratory syncytial virus has now gained market clearance. 

    For subscribers

  • Foto: Mike Blake/Reuters/Ritzau Scanpix

    Obesity shot frenzy makes Eli Lilly world’s most valuable drugmaker

    After a strong May, Eli Lilly surpasses Johnson & Johnson on market values, becoming the biggest pharma firm in the world. 

    For subscribers

Latest news

  • EU Commission approves first RSV vaccine for people over 60 – 7 Jun
  • Snipr Biome shelves lead candidate: "It’s hard to make money within AMR" – 7 Jun
  • UK looks to expand obesity-drug access with pilot program – 7 Jun
  • Denmark warns against overtreatment with Ozempic – 7 Jun
  • Takeda, Eli Lilly must defend racketeering suit over diabetes drug, judge rules – 7 Jun
  • Merck sues US, calling move to cut drug prices "extortion" – 7 Jun
  • Analyst predicts golden future for GLP-1 as drugmakers rush to join in – 7 Jun
  • Zealand Pharma reprimanded by Danish watchdog following sale of rescue pen to Novo Nordisk – 6 Jun
  • US contract manufacturer acquires Danish consultancy firm – 6 Jun
  • Genmab approval marks the era of bispecific antibodies in blood cancer treatment, says expert – 6 Jun
See all

Jobs

  • QA Project Manager - ensure high-quality health care products

  • Experienced Scientist, Oncology Research

  • Senior Test Engineer

  • Senior/Principal Scientist Pharmacology & Biology, Synklino

  • Endpoint Engineer

  • Team Manager, Analytical Chemistry

  • Academic staff member for Environmental Monitoring - Aseptic Production

  • Medical Writer

  • Test Engineer

  • Senior Quality Specialist Business Support Team, Medical Devices, Ferrosan

  • Senior Scientist, Analytical Development

  • Senior Principle Project Portfolio Manager

  • Regulatory Affairs Specialist

  • Design Control Specialist - ensure safe, high-quality products

  • Senior/Principal CMC Development Scientist, Synklino

  • Regulatory Affairs Associate

  • Experienced Bioanalytical Scientist

  • Manager of Quality Assurance Operation Support Team, Medical Devices, Ferrosan Medical Devices

  • Chief Commercial Officer

  • Senior Process Engineer with Project Experience

  • IT Infrastructure Engineer

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved